Evaluation of threats to cash flows from the U.S. prescription drug market.

Details

Supervisors

Cornuel, Eric

Faculty

Louvain School of Management

Degree label

Master [60] en sciences de gestion (horaire décalé)

Abstract

Reception of letters denying access to the American market can be very damaging for a pharmaceutical company. Indeed, such a letter, at best, delays important cash flows and therefore impacts the ability to finance other projects and to meet shareholders expectations. This work, after covering the basic necessary knowledge, considers the sources of risks to the cash flows from the lucrative US market. As the discussions moves forward, it appears that money, time and politics are at the heart of every potential problem.